I got breast cancer at 30. Now, because of my treatment, I have to wait 5 to 10 years to have kids, and I'm mourning the ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...

AstraZenecas experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone ...

Male patients with ER+ breast cancer tend to have grade 2 or 3 tumors, stage II or III disease, and progesterone receptor-positivity compared to female patients.

In this video, Erica L. Mayer, MD, MPH, discusses the SERENA-6 study, which assessed the efficacy of switching to camizestrant plus a CDK 4/6 inhibitor vs. continuing standard treatment among patients ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.